Melanotan II is a synthetic cyclic analog of α-MSH, and it acts as a non-selective agonist across all four melanocortin receptors, MC1R, MC3R, MC4R, and MC5R. It mimics melanocortin signaling, so MC1R drives eumelanin production and pigmentation, while central MC4R influences appetite, energy balance, and sexual signaling. It also crosses the blood-brain barrier, supporting CNS actions. Understanding each receptor’s role reveals why this peptide behaves the way it does.
Key Takeaways
- Melanotan II is a synthetic cyclic analog of α-melanocyte-stimulating hormone (α-MSH) functioning as a non-selective melanocortin receptor agonist.
- It engages MC1R, MC3R, MC4R, and MC5R, with broad engagement attributed to limited discrimination across the receptor family.
- MC1R activation drives melanocyte stimulation and eumelanin production, while MC4R centrally influences appetite, energy balance, and sexual signaling.
- Its cyclic structure supports blood-brain barrier penetration, enabling central nervous system actions on appetite and sexual signaling.
- Research spans pigmentation, appetite, sexual function, neuroprotection, and addiction-related models across melanocortin signaling pathways.
What is Melanotan II in melanocortin receptor research
Melanotan II is a synthetic cyclic analog of α-melanocyte-stimulating hormone (α-MSH) used in melanocortin receptor research as a non-selective melanocortin receptor agonist. It engages MC1R, MC3R, MC4R, and MC5R rather than targeting a single subtype. That broad receptor profile distinguishes it from more selective follow-on compounds and explains its wide research utility. Its cyclic peptide structure supports this promiscuous receptor engagement, driving both desired endpoints and off-target effects. It penetrates the blood-brain barrier, which accounts for its central nervous system actions on appetite and sexual signaling. In research settings, it is examined across pigmentation, feeding behavior, erectile function, and neuroprotection. Keep in mind it’s not approved for any therapeutic indication.
What are melanocortin receptors
Melanocortin receptors are a family of G-protein-coupled receptors that respond to melanocortin peptides like α-MSH. Melanotan II engages four of them: MC1R, MC3R, MC4R, and MC5R. Each receptor drives distinct physiology. MC1R sits on melanocytes, where activation promotes eumelanin production and darker pigmentation. MC4R operates centrally, influencing appetite, energy balance, and sexual signaling. MC3R and MC5R contribute additional metabolic and peripheral effects. Because Melanotan II binds across this whole family rather than selectively, you get both intended endpoints, tanning, appetite suppression, erectile response, and off-target adverse effects. Understanding each receptor’s location and downstream signaling helps you interpret why this compound behaves so broadly.
Which receptors does Melanotan II target
Melanotan II targets MC1R, MC3R, MC4R, and MC5R as a non-selective melanocortin receptor agonist. It is a synthetic cyclic analog of α-melanocyte-stimulating hormone (α-MSH), engineered to mimic melanocortin signaling. It does not discriminate much across the receptor family.
When it engages MC1R, it drives melanocyte stimulation and eumelanin production. When it hits MC4R, it influences appetite, energy balance, and sexual signaling.
This broad receptor engagement stems from its cyclic peptide structure, which distinguishes it from more selective follow-on compounds. You should recognize the trade-off: non-selective binding explains both the desired endpoints you’re studying and the off-target adverse effects observed in studies. It also penetrates the blood-brain barrier.
What research background exists for Melanotan II
Melanotan II has a research background spanning pigmentation, appetite, sexual function, neuroprotection, and addiction-related models, with effects tied to specific melanocortin signaling pathways. Pigmentation studies use MC1R-mediated melanogenesis, where eumelanin synthesis drives pigmentation without UV exposure, alongside reported oral mucosa darkening. Appetite research exploits central MC4R signaling: MT-II microinjected into the nucleus accumbens cuts food intake in mice, though chronic dosing produces tolerance. Sexual-function work builds on MC4R activation too, a human crossover trial induced erections in 17 of 20 men with ED, absent sexual stimulation. Neuroprotection studies show improved sensory recovery after sciatic nerve crush and partial protection against cisplatin neuropathy. Research has also examined addiction-related models where MT-II blunts ethanol intake, all reflecting non-selective melanocortin engagement.
How does Melanotan II compare to related compounds
Melanotan II differs from related compounds by being non-selective, agonizing MC1R, MC3R, MC4R, and MC5R rather than targeting a single receptor. This broad melanocortin engagement contrasts with more selective follow-on peptides designed to isolate specific endpoints. Its cyclic structure drives this wide receptor binding, explaining both desired effects and off-target adverse signals.
| Feature | Melanotan II |
|---|---|
| Receptor selectivity | Non-selective (MC1R, MC5R) |
| MC1R potency | Weaker than melanotan I |
| Structure | Cyclic peptide |
Notably, one review describes Melanotan II as weaker than melanotan I for MC1R activation, so it’s not the strongest pigmentation driver. Its value lies in probing multiple melanocortin pathways simultaneously, whereas selective analogs sacrifice breadth for cleaner receptor-specific readouts.
How to source and store research-grade Melanotan II
Source research-grade Melanotan II as lyophilized peptide verified by HPLC and mass spectrometry, and store it at −20°C protected from light and moisture. Because Melanotan II is a cyclic peptide with broad melanocortin receptor activity, its integrity directly determines whether the MC1R and MC5R readouts stay reliable. Sequence errors or truncations shift receptor affinity and skew eumelanin, appetite, and erectile-signaling endpoints. Confirm purity documentation before you commit to any dosing protocol.
Store the lyophilized powder at −20°C, protected from light and moisture, because oxidation and hydrolysis degrade the cyclic structure and blunt agonist potency. Reconstituted with bacteriostatic water, keep it refrigerated at 2,8°C and use it within weeks, since dissolved peptide destabilizes faster.
Label every aliquot, track freeze-thaw cycles, and discard degraded material to protect the mechanistic conclusions across MC4R-driven experiments.
Order Lab-Verified Peptides for Melanocortin Studies
Whether your research explores melanocortin receptor binding or related pathways, starting with a trusted supplier saves time and improves outcomes. Every batch at Holas is backed by independent lab results for verified purity and consistency. Browse our full catalog or reach out to discuss your sourcing needs.
Frequently Asked Questions
Is Melanotan II Approved for Any Therapeutic or Clinical Use?
No, Melanotan II is not approved for any therapeutic or clinical indication. It is a non-selective melanocortin receptor agonist, engaging MC1R, MC3R, MC4R, and MC5R, and it remains strictly a research compound. Studies have probed its effects on pigmentation, appetite, erectile signaling, and neuroprotection in research models, but its broad receptor engagement is associated with off-target effects such as nausea, yawning, and fatigue in reported data. No regulatory approval supports any clinical use.
What Adverse Effects Are Associated With Melanotan II?
Research literature associates several adverse effects with Melanotan II’s non-selective melanocortin activation. Nausea and yawning are among the most commonly reported, and in one study at 0.025 mg/kg roughly 12.9% of subjects reported severe nausea. Fatigue, reduced food intake, and penile erection have also been documented, driven by broad melanocortin receptor engagement. These observations come from research data rather than any approved use.
Does Melanotan II Require UV Exposure to Affect Pigmentation?
Not necessarily. Melanotan II directly activates MC1R on melanocytes, driving melanogenesis and increasing eumelanin synthesis independent of ultraviolet light. Research descriptions note pigmentation changes without direct UV exposure, though UV-mediated effects may be amplified rather than fully replaced. In research models, darkening can occur on its own, while UV appears to further amplify the pigmentary response through the same melanocortin-driven pathway.
What Doses Were Used in Melanotan II Research Studies?
Several doses appear across the research literature. In one sexual-function study, subjects received 0.025 mg/kg, with about 12.9% reporting severe nausea. Neuroprotection work in rats used 20 μg/kg subcutaneously every 48 hours, which improved sensory recovery after sciatic nerve crush and partially protected against cisplatin-induced neuropathy. Appetite studies used central microinjection into the nucleus accumbens rather than weight-based dosing, targeting melanocortin signaling directly to reduce food intake without metabolic changes.
Can Tolerance Develop to Melanotan II’s Effects Over Time?
Research indicates tolerance can develop to some of Melanotan II’s effects. Chronic rat studies have reported tolerance specifically to its suppression of food intake, meaning the appetite-blunting response through central melanocortin signaling weakens with repeated dosing in those models. This reflects receptor-level adaptation consistent with sustained MC4R activation. The finding comes from animal research rather than any human or clinical context.
